MADCAM1 and inflammatory bowel disease: In IBD, targeting the α4β7-MAdCAM-1 interaction with vedolizumab has shown efficacy in clinical trials and possesses an advantage with regard to safety due to the selectivity of said interaction to the gut, as does targeting β7-chain on its own with etrolizumab.